CRISPR Therapeutics AG CRSP Income Statement (2015-2026)

NASDAQ CRSP
$55.78 -0.71 (-1.26%)
As of: Sep 4, 2026 · 2:23 PM EDT
Reported Financials

CRISPR Therapeutics AG Quarterly Income Statement

Periods 44 quarters
Latest Jun 2026

CRISPR Therapeutics AG reported revenue of $10.18M and net income of -$93.84M for the quarter ended Jun 2026. This income statement covers 44 quarters of results from Sep 2015 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
76.46M76.99M77.39M77.79M78.25M78.51M78.86M79.37M79.43M80.04M84.84M85.05M85.34M85.74M86.36M88.38M93.87M95.89M96.39M96.66M
Revenue & cost
Revenue
0.82M12.90M0.94M0.16M0.09M0.01M100.00M70.00M201.21M0.50M0.52M0.60M35.69M0.86M0.89M0.89M0.86M1.46M10.18M
Operating items
Research & DevelopmentR&D
83.50M103.09M118.25M123.22M116.62M103.56M99.94M101.56M90.70M95.14M76.17M80.17M82.16M71.74M72.48M69.89M58.90M13.00M68.57M67.15M
Selling, General & AdministrativeSG&A
23.71M23.68M28.02M26.27M27.00M21.17M22.36M19.03M18.29M16.48M17.95M19.48M17.42M18.12M19.30M18.92M16.93M18.40M17.18M17.55M
Other Operating ExpensesOther Opex
22.46M31.82M30.65M33.92M38.86M6.82M42.19M44.64M23.42M20.00M46.97M52.13M11.15M10.42M57.51M141.41M57.12M124.23M45.95M42.74M
Operating ExpensesOpex
129.67M158.60M176.91M183.42M182.48M131.55M164.49M165.22M132.41M131.62M141.09M151.78M110.73M100.28M149.29M230.22M132.95M155.63M131.71M127.45M
Operating IncomeOp. Inc
-128.85M-145.70M-175.97M-183.26M-182.39M-131.54M-64.49M-95.22M-132.41M69.58M-140.59M-151.26M-110.13M-64.59M-148.42M-229.32M-132.06M-154.76M-130.25M-117.27M
EBIT
-128.85M-145.70M-175.97M-183.26M-182.39M-131.54M-64.49M-95.22M-132.41M69.58M-140.59M-151.26M-110.13M-64.59M-148.42M-229.32M-132.06M-154.76M-130.25M-117.27M
Non-operating items
Interest & Investment IncomeInt & Inv Inc
-0.12M-4.30M-11.80M-3.38M-1.82M6.50M6.23M0.45M2.16M8.65M-3.45M-1.33M13.37M-8.64M2.25M-0.17M0.97M-0.17M-6.73M-2.69M
Other Non Operating IncomeOther Non Op Inc.
1.10M2.20M0.36M3.54M7.26M11.49M12.74M18.41M20.67M20.00M24.72M26.14M25.06M27.98M13.54M22.07M26.24M24.77M8.16M27.07M
Non Operating IncomeNon Op. Inc.
1.10M2.20M0.36M3.54M7.26M11.49M12.74M18.41M20.67M20.00M24.72M26.14M25.06M27.98M13.54M22.07M26.24M24.77M8.16M27.07M
Net income details
EBT
-127.75M-143.50M-175.61M-179.72M-175.12M-121.37M-51.74M-76.82M-111.74M59.22M-115.87M-125.12M-85.07M-77.84M-134.89M-207.26M-105.82M-162.53M-122.09M-90.19M
Tax ProvisionsTaxes
-0.60M-2.25M3.61M6.12M-0.60M-8.52M1.32M0.92M0.41M0.61M0.72M1.30M0.90M1.17M1.11M1.30M0.62M0.61M0.84M1.00M
Profit After TaxPAT
-127.29M-141.25M-179.22M-185.83M-176.47M-103.96M-53.06M-77.74M-112.15M89.35M-116.59M-126.41M-85.94M-37.38M-136.00M-208.64M-106.44M-130.61M-122.93M-93.84M
Equity Income
Income from Non-Controlling InterestsInc. Minority
Income from Continuing OperationsIncome (Continuing)
-127.15M-141.25M-179.22M-185.83M-174.52M-112.86M-53.06M-77.74M-112.15M58.61M-116.59M-126.42M-85.97M-79.01M-136.00M-208.56M-106.44M-163.14M-122.93M-91.19M
Consolidated Net IncomeConsol Net Inc.
-127.15M-141.25M-179.22M-185.83M-174.52M-112.86M-53.06M-77.74M-112.15M58.61M-116.59M-126.42M-85.97M-79.01M-136.00M-208.56M-106.44M-163.14M-122.93M-91.19M
Income towards Parent CompanyParent Net Inc
-127.15M-141.25M-179.22M-185.83M-174.52M-112.86M-53.06M-77.74M-112.15M58.61M-116.59M-126.42M-85.97M-79.01M-136.00M-208.56M-106.44M-163.14M-122.93M-91.19M
Net Income towards Common StockholdersNet Income
-127.15M-141.25M-179.22M-185.83M-174.52M-112.86M-53.06M-77.74M-112.15M58.61M-116.59M-126.42M-85.97M-79.01M-136.00M-208.56M-106.44M-163.14M-122.93M-91.19M
Additional items
EPS (Basic)
-1.67-1.86-2.32-2.40-2.24-1.45-0.67-0.98-1.410.74-1.43-1.49-1.01-0.94-1.58-2.40-1.17-1.81-1.28-0.94
EPS (Diluted)
-1.67-1.76-2.32-2.40-2.24-1.45-0.67-0.98-1.410.74-1.43-1.49-1.01-0.94-1.58-2.40-1.17-1.81-1.28-0.94
Shares Outstanding
76.29M75.95M77.10M77.51M78.02M77.75M78.68M79.09M79.41M79.22M81.79M84.92M85.23M84.36M85.94M87.07M91.31M89.93M96.05M96.51M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
76.29M80.39M77.10M77.51M78.02M77.75M78.68M79.09M79.41M79.22M81.79M84.92M85.23M84.36M85.94M87.07M91.31M89.93M96.05M96.51M
EBITDA
-128.85M-145.70M-175.97M-183.26M-182.39M-131.54M-64.49M-95.22M-132.41M69.58M-140.59M-151.26M-110.13M-64.59M-148.42M-229.32M-132.06M-154.76M-130.25M-117.27M
Tax Rate
0.471.57-2.05-3.400.347.02-2.55-1.20-0.371.03-0.62-1.04-1.06-1.50-0.82-0.63-0.58-0.38-0.69-1.11